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IMPORTANCE Hypertension is themost important preventable cause of morbidity and
mortality globally, yet there are relatively few data collected using standardizedmethods.
OBJECTIVE To examine hypertension prevalence, awareness, treatment, and control in
participants at baseline in the Prospective Urban Rural Epidemiology (PURE) study.
DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study of 153 996 adults (complete
data for this analysis on 142 042) aged 35 to 70 years, recruited between January 2003 and
December 2009. Participants were from 628 communities in 3 high-income countries (HIC),
10 upper–middle-income and low–middle-income countries (UMIC and LMIC), and 4
low-income countries (LIC).
MAIN OUTCOMES ANDMEASURES Hypertensionwas defined as individuals with self-reported
treated hypertension or with an average of 2 blood pressure measurements of at least
140/90mmHg using an automated digital device. Awareness was based on self-reports,
treatment was based on the regular use of blood pressure–lowering medications, and control
was defined as individuals with blood pressure lower than 140/90mmHg.
RESULTS Among the 142 042 participants, 57 840 (40.8%; 95% CI, 40.5%-41.0%) had
hypertension and 26 877 (46.5%; 95% CI, 46.1%-46.9%) were aware of the diagnosis. Of
those whowere aware of the diagnosis, the majority (23 510 [87.5%; 95% CI, 87.1%-87.9%] of
those whowere aware) were receiving pharmacological treatments, but only a minority of
those receiving treatment were controlled (7634 [32.5%; 95% CI, 31.9%-33.1%]). Overall,
30.8%, 95% CI, 30.2%-31.4% of treated patients were taking 2 or more types of blood
pressure–lowering medications. The percentages aware (49.0% [95% CI, 47.8%-50.3%] in
HICs, 52.5% [95% CI, 51.8%-53.2%] in UMICs, 43.6% [95% CI, 42.9%-44.2%] in LMICs, and
40.8% [95% CI, 39.9%-41.8%] in LICs) and treated (46.7% [95% CI, 45.5%-47.9%] in HICs,
48.3%, [95% CI, 47.6%-49.1%] in UMICs, 36.9%, [95% CI, 36.3%-37.6%] in LMICs, and 31.7%
[95% CI, 30.8%-32.6%] in LICs) were lower in LICs compared with all other countries for
awareness (P <.001) and treatment (P <.001). Awareness, treatment, and control of
hypertension were higher in urban communities compared with rural ones in LICs (urban vs
rural, P <.001) and LMICs (urban vs rural, P <.001), but similar for other countries. Low
education was associated with lower rates of awareness, treatment, and control in LICs, but
not in other countries.
CONCLUSIONS AND RELEVANCE Among amultinational study population, 46.5% of
participants with hypertension were aware of the diagnosis, with blood pressure control
among 32.5% of those being treated. These findings suggest substantial room for
improvement in hypertension diagnosis and treatment.
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H igh blood pressure is the leading cause of cardiovas-cular disease (CVD) and deaths globally. It is associ-ated with at least 7.6 million deaths per year world-
wide (13.5%of all deaths),making it the leading risk factor for
CVD.1 The majority of CVD occurs in low-, low–middle-, and
upper–middle-incomecountries (LIC,LMIC, andUMIC).1,2 The
importanceofbloodpressureasamodifiable risk factor forCVD
iswell-recognized andmany effective and inexpensive blood
pressure–lowering treatments are available. Therefore, hyper-
tension control and prevention of subsequent morbidity and
mortality clearly should be achievable.
Information on hypertension prevalence, awareness,
treatment, and control in multiple countries and different
types of communities is necessary to provide a baseline for
monitoring and also to inform the development of new
strategies for improving
hypertension control. A
number of initiatives
from the World Health
Organ izat ion (WHO)
have documented preva-
lence of hypertension
and some have recorded
treatment rates.3-5 The
largest systematic analy-
sis of health surveys
from 199 countries for
individuals aged 25 years and older was conducted in 2008
and reported the prevalence and mean of hypertension.6
However, most studies were limited to few countries and
were conducted at least 2 decades ago, few reported aware-
ness, and none reported on variations between urban vs
rural settings, economic status and other variables, rates of
blood pressure control, or the types of treatments used.
Such information is key to developing strategies for better
detection and control of hypertension globally.
Theoverall ProspectiveUrbanRuralEpidemiology (PURE)
study is a prospective, standardized collaborative study7,8 in
which we report a cross-sectional analysis of baseline data to
assess theprevalence, awareness, treatment, andcontrolofhy-
pertensionby theeconomic statusof countries andby sex, age
group, location (urban vs rural), and education of the partici-
pants.
Methods
The PURE study was approved by the ethics committees in
all participating centers. All participants provided consent
(either written or a thumbprint if unable to read). The PURE
study involves urban and rural communities within 17 coun-
tries including 3 high-income countries (HICs): Canada,
Sweden, United Arab Emirates; (7 UMICs) Argentina, Brazil,
Chile, Poland, Turkey, Malaysia, South Africa; (3 LMICs)
China, Colombia, Iran; and (4 LICs) Bangladesh, India, Paki-
stan, Zimbabwe (eTable 8 in Supplement). Categorization of
economic level of a country was based on information from
the World Bank in 2006.9 The overall aim of PURE was to
examine the relationship of societal influences on lifestyle
behaviors, cardiovascular risk factors, and incidence and
mortality of chronic diseases. The methods of the PURE
study have been described previously.10,11 Briefly, countries
and communities were chosen purposively to participate in
PURE. For practical reasons, our goal was not to select strict
proportionate sampling, but instead to show economic and
sociocultural diversity and inclusion of sites in which inves-
tigators were committed to collecting high-quality data at a
modest budget and to following up participants for at least
10 years. Within communities, the sampling framework
used aimed to recruit an unbiased sample of households.10
Inclusion of a broad sample of several countries of low- and
middle-income status, countries in which data on chronic
disease are relatively sparse, was a key goal. Within each
country, an urban and rural stratified sample of communi-
ties was selected with the aim to include a diverse range of
communities (eTable 8 in Supplement). In the analysis by
region, South Asia includes cohorts from Bangladesh, India,
and Pakistan; Africa includes South Africa and Zimbabwe;
North America and the European Union includes Canada,
Sweden, and Poland; the Middle East includes Iran, Turkey,
and the United Arab Emirates; South America includes
Argentina, Brazil, Chile, and Colombia; while China and
Malaysia included cohorts from their respective countries
only.
Households were eligible if 1 or more members of the
household was aged between 35 and 70 years and the house-
holdmembers intended to stay at that address for a further 4
years.Medical history and risk factorswere recordedandaba-
sic physical examination was conducted on participants be-
tween the ages of 35 and 70 years who provided written in-
formed consent.10,11
Measurement of Risk Factors
CVD risk factor history, including smoking, history of hyper-
tension, diabetes, psychosocial factors, alcohol consump-
tion, andphysicalmeasureswere recordedasdescribed in the
INTERHEART study,12 as were sociodemographic character-
istics includingdate of birth.Withparticipants forwhomdate
ofbirthwasunknown, self-reportedagewas recorded inyears.
Younger age was defined as less than 50 years, and older was
defined as aged 50 years or older. In these analyses, prevalent
diabetes and CVD are defined on the basis of self-reported
medical diagnoses,whichhavedemonstrated substantial and
moderateagreement,13 respectivelywithdata fromdisease reg-
isters in a largeFinnish study (κ, 0.58 and0.75).14Wealsoveri-
fied, during a central adjudication process, medical or hospi-
tal records in a sample of 455 events during follow-up with
agreement rates of 89%.11 Education was categorized as high
(tradeschool, collegeoruniversity);medium(secondaryschool
or high school), low (primary education or no education), or
unknown.
Sitting blood pressure was measured by trained research
assistants at all centers following a standardized procedure
using an Omron digital blood pressure measuring device
(Omron HEM-757) provided for all sites. The mean of 2 mea-
sures was used for all analyses. The main hypertension defi-
ACE angiotensin-converting enzyme
ARB angiotensin receptor blocker
CVD cardiovascular disease
DBP diastolic blood pressure
HIC high-income country
LIC low-income country
LMIC low–middle-income country
SBP systolic blood pressure
UMIC upper–middle-income country
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nition used in this article was individuals who reported hav-
ing hypertension and receiving blood pressure-lowering
treatment or had an average systolic blood pressure (SBP) of
at least 140 mm Hg, an average diastolic blood pressure
(DBP) of at least 90 mm Hg (categorized as stage 1), or both
an SBP and DBP that exceeded the previously shown levels.
We also used a similar definition similar to categorize stage
2 participants but included individuals with SBP of at least
160 mm Hg, DBP of at least 100 mm Hg (or both, as previ-
ously shown). Categorizing stage 1 vs stage 2 was done to
demonstrate the distribution of definite hypertension. All
participants were asked whether they had a medical diagno-
sis of hypertension (awareness), whether they were receiv-
ing blood pressure-lowering medications (treatment), and a
list of all their medications were recorded. Control was the
proportion of participants with hypertension who had an
average systolic and diastolic blood pressure of less than
140/90 mm Hg.
Statistical Analysis
Results arepresentedas thenumbers (and correspondingper-
centages) for categorical variables andmean (SD) for continu-
ous variables. To enable comparison with other global esti-
mates of hypertension, we conducted age and sex direct
standardization15 using the WHO world population.16 To en-
able comparison between subgroups and to control for clus-
tering, resultswere adjustedusing a generalized linearmixed-
effectmodel. Specifically,weused theGLIMMIXprocedure in
SAS assuming community as a random effect and other fac-
tors such as age, sex, location, education and income status
of the country as fixed effects in the model. For binary out-
comes,weused thebinomial distributionoptionwith the logit
link function.
Interaction between variables was also tested by includ-
ing an appropriate term in themodel.When interactionswere
found to be significant, strata-specific models were used for
adjusted rates. Means were compared using t tests or medi-
ans and/or proportion compared with appropriate nonpara-
metric tests. To ensure that all tests took into account the ef-
fect of clustering, different groups were compared based on
thePvaluesobtained fromthemixed-effectmodel and the lin-
ear test of trendwasperformedusingmodel coefficients from
mixedmodelsandanappropriatecontrast statement.APvalue
of less than .01 was considered to be statistically significant
with a 2-sided alternative. All statistical analyses were calcu-
latedusing SAS software version9.2 (SAS Institute Inc) and all
figureswere drawnusing S-PLUS software version 6.2 (TIBCO
Software Inc).
Table 1. Characteristics of Participants by Country and Hypertension Level According to Various Definitions
Countrya
No. of
Participants
No. (%) Mean (SD)
Self-reported Hypertension
Characteristics, No. (%)
Rural Women Age, y
Systolic BP,
mm Hg
Diastolic BP,
mm Hg
Receiving
Treatment
Receiving
Treatment or
BP ≥140/90
mm Hg
Receiving
Treatment or
BP ≥160/100
mm Hg
HIC 15 418 4426 (28.7) 8398 (54.5) 52.91 (9.2) 130.5 (19.7) 81.8 (12.3) 2763 (18.0) 6263 (40.7) 3716 (24.1)
Canada 10 349 3095 (29.9) 5552 (53.6) 53.36 (9.1) 129.2 (19.4) 79.6 (11.3) 1959 (19.0) 3865 (37.5) 2367 (22.9)
Sweden 4151 902 (21.7) 2193 (52.8) 52.65 (9.0) 132.7 (19.6) 86.7 (13.0) 572 (13.8) 1921 (46.3) 1041 (25.1)
United Arab
Emirates
918 429 (46.7) 653 (71.1) 49.14 (10.2) 135.1 (21.4) 83.9 (11.9) 232 (25.3) 477 (52.0) 308 (33.6)
UMIC 36 463 17 074 (46.8) 21 900 (60.1) 51.19 (9.4) 134.5 (23.1) 83.4 (20.4) 8290 (22.7) 18 123 (49.7) 11 727 (32.2)
Argentina 7424 3871 (52.1) 4568 (61.5) 51.15 (9.8) 135.2 (21.7) 82.8 (12.6) 1844 (24.8) 3777 (50.9) 2440 (32.9)
Brazil 5549 1925 (34.7) 3071 (55.3) 52.21 (9.3) 132.3 (23.8) 86.7 (38.0) 1788 (32.2) 2918 (52.6) 2113 (38.1)
Chile 3186 640 (20.1) 2115 (66.4) 51.88 (9.7) 130.8 (22.1) 82.1 (20.5) 753 (23.6) 1485 (46.6) 1003 (31.5)
Malaysia 11 324 6853 (60.5) 6448 (56.9) 51.13 (9.2) 135.2 (22.8) 81.7 (15.5) 2090 (18.5) 5321 (47.0) 3221 (28.4)
Poland 1947 755 (38.8) 1215 (62.4) 53.82 (8.9) 145.2 (21.8) 86.1 (11.5) 628 (32.4) 1307 (67.3) 880 (45.2)
South Africa 3031 1633 (53.9) 2058 (67.9) 49.25 (9.2) 138.0 (25.7) 89.2 (15.2) 408 (13.5) 1726 (57.1) 1042 (34.4)
Turkey 4002 1397 (34.9) 2425 (60.6) 49.70 (9.0) 129.5 (22.2) 80.4 (13.1) 779 (19.5) 1589 (39.7) 1028 (25.7)
LMIC 58 476 29 353 (50.2) 34 403 (58.8) 50.68 (9.6) 132.1 (22.4) 82.1 (13.7) 8294 (14.2) 23 269 (39.9) 13 344 (22.8)
China 45 108 22 722 (50.4) 26 551 (58.9) 50.96 (9.6) 133.7 (22.4) 82.9 (13.2) 6311 (14.0) 18 915 (42.0) 10 693 (23.7)
Colombia 7355 3649 (49.6) 4715 (64.1) 50.73 (9.5) 128.8 (23.3) 81.1 (16.9) 1241 (16.9) 2757 (37.5) 1723 (23.4)
Iran 6013 2982 (49.6) 3137 (52.2) 48.48 (9.2) 124.5 (18.7) 77.6 (11.5) 742 (12.3) 1597 (26.6) 928 (15.4)
LIC 31 685 16 707 (52.7) 17 906 (56.5) 48.55 (10.3) 126.38 (21.8) 80.4 (13.0) 3121 (9.9) 10 185 (32.2) 5557 (17.5)
Bangladesh 2754 1437 (52.2) 1508 (54.8) 46.00 (9.4) 127.0 (23.3) 84.5 (14.9) 155 (5.7) 1079 (39.3) 598 (21.7)
India 26 861 14 362 (53.5) 15 167 (56.5) 48.77 (10.4) 126.0 (21.1) 79.6 (12.6) 2698 (10.1) 8240 (30.7) 4432 (16.5)
Pakistan 1288 370 (28.7) 670 (52.0) 47.38 (8.7) 124.16 (21.1) 82.7 (12.3) 153 (11.9) 432 (33.5) 242 (18.8)
Zimbabwe 782 538 (68.8) 561 (71.7) 51.96 (9.5) 142.53 (32.1) 88.8 (16.3) 115 (14.7) 434 (55.6) 285 (36.4)
All countries 142 042 67 560 (47.6) 82 607 (58.2) 50.58 (9.7) 131.28 (22.4) 82.0 (15.5) 22 468 (15.8) 57 840 (40.8) 34 344 (24.2)
Abbreviations: BP, blood pressure; HIC, high-income country; LIC, low-income
country; LMIC, low–middle-income country; UMIC, upper–middle-income
country.
a Categorization of economic level of a country was based on information from
theWorld Bank in 2006. Participants from all countries were recruited
between 2005 and 2010.
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Results
ThePUREstudyenumerated382 341 individuals from107 599
households in 628 communities (348 urban and 280 rural) in
17 countries on 5 continents. Recruitment started in Karna-
taka, India in January 2003; however,most communitieswere
recruitedbetween January 2005, andDecember 2009.Among
theenumerated individuals, 197 332 (52%)werebetween35and
70 years of age and 153 996 (78%) of these adults consented
to participate in both the interview and physical examina-
tion. Response rateswere calculated as the numbers enrolled
or recruited participants divided by the eligible number of in-
dividuals in all of the households approached for the study.
Rates of responsewere similar inHIC (84%), UMIC (87%), and
LMIC (82%), but lower in LIC (55%). The average age of par-
ticipants and thepercentwith primary or less educationwere
similar, but thepercentageofwomenwashigher among those
enrolled compared with those who were eligible. This pat-
tern was similar in HIC, UMIC, LMIC, and LIC. At the analysis
Table 2. Prevalence of Awareness, Treatment, and Control Among the Hypertensive Population in PURE
According to 2 Definitions
Variables
No. (%) of Participants
Overall Aware Treated Controlled
Proportion With BP
<140/90 mm Hg
Among Those
Receiving Treatment
Self-reported hypertension with
treatment or BP ≥140/90 mm Hg
Income level
HIC 6263 3070 (49.0) 2924 (46.7) 1189 (19.0) 1189 (40.7)
UMIC 18 123 9516 (52.5) 8761 (48.3) 2833 (15.6) 2833 (32.3)
LMIC 23 269 10 134 (43.6) 8595 (36.9) 2314 (9.9) 2314 (26.9)
LIC 10 185 4157 (40.8) 3230 (31.7) 1298 (12.7) 1298 (40.2)
Sex
Women 32 649 16 440 (50.4) 14 491 (44.4) 4891 (15.0) 4891 (33.8)
Men 25 191 10 437 (41.4) 9019 (35.8) 2743 (10.9) 2743 (30.4)
Regiona
South Asia 9751 3942 (40.4) 3113 (31.9) 1264 (13.0) 1264 (40.6)
China 18 915 7866 (41.6) 6503 (34.4) 1545 (8.2) 1545 (23.8)
Malaysia 5321 2568 (48.3) 2226 (41.8) 680 (12.8) 680 (30.5)
Africa 2160 743 (34.4) 677 (31.3) 140 (6.5) 140 (20.7)
North America and Europe 8682 4428 (51.0) 4158 (47.9) 1599 (18.4) 1599 (38.5)
Middle East 2074 1088 (52.5) 1054 (50.8) 354 (17.1) 354 (33.6)
South America 10 937 6242 (57.1) 5779 (52.8) 2052 (18.8) 2052 (35.5)
All included continents, countries,
or regions
57 840 26 877 (46.5) 23 510 (40.6) 7634 (13.2) 7634 (32.5)
Self-reported hypertension with
treatment or blood pressure
≥160/100 mm Hg
Income level
HIC 3716 2895 (78.0) 2803 (75.5) 1189 (32.0) 1189 (42.4)
UMIC 11 727 8929 (76.2) 8513 (72.6) 2833 (24.2) 2833 (33.3)
LMIC 13 344 9307 (69.8) 8422 (63.2) 2314 (17.4) 2314 (27.5)
LIC 5557 3600 (64.8) 3162 (57.0) 1298 (23.4) 1298 (41.0)
Sex
Women 20 223 15 194 (75.2) 14 166 (70.1) 4891 (24.2) 4891 (34.5)
Men 14 121 9537 (67.6) 8734 (61.9) 2743 (19.4) 2743 (31.4)
Regiona
South Asia 5272 3419 (64.9) 3046 (57.8) 1264 (24.0) 1264 (41.5)
China 10 693 7188 (67.3) 6408 (60.0) 1545 (14.5) 1545 (24.1)
Malaysia 3221 2337 (72.6) 2161 (67.1) 680 (21.1) 680 (31.5)
Africa 1327 670 (50.6) 618 (46.6) 140 (10.6) 140 (22.7)
North America and Europe 5316 4163 (78.4) 4003 (75.4) 1599 (30.1) 1599 (39.9)
Middle East 1236 1028 (83.2) 993 (80.3) 354 (28.6) 354 (35.6)
South America 7279 5926 (81.4) 5671 (77.9) 2052 (28.2) 2052 (36.2)
All included continents, countries,
or regions
34 344 24 731 (72.1) 22 900 (66.7) 7634 (22.2) 7634 (33.3)
Abbreviations: BP, blood pressure;
HIC, high-income country; LIC,
low-income country; LMIC,
low–middle-income country; UMIC,
upper–middle-income country.
a Countries within regional analyses
include Bangladesh, India, and
Pakistan (for South Asia), South
Africa and Zimbabwe (for Africa),
Canada, Sweden, and Poland (for
North America/European Union),
Iran, Turkey, and the United Arab
Emirates (for theMiddle East),
Argentina, Brazil, Chile, and
Colombia (for South America), and
China andMalaysia, which each
include cohorts from their
respective countries only.
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stage, we excluded individuals whowere outside the age cri-
teria, leaving 151 966participants. Thosewith incomplete sys-
tolic and diastolic blood pressure measures were also ex-
cluded, leaving 142 042 to constitute the population used in
this report.17
Table 1 summarizes the characteristics of the cohort and
the prevalence of hypertension according to different defini-
tions.Overall, 57 840of theparticipants enrolled inPUREhad
hypertension (40.8%; 95% CI, 40.5-41.0) and themean blood
pressurewas 131/82mmHg. The age and sexprevalence stan-
dardized to theWHOworld populationwas 27.7%. The distri-
bution, based on different definitions, is detailed online
(eTables 1-4 in Supplement).
Awareness, Treatment, and Control of Hypertension
Among participants with hypertension, 26 877were aware of
their condition (46.5%; 95%CI, 46.1%-46.9%), 23 510were re-
ceiving treatment (40.6%; 95% CI, 40.2%-41.0% [87.5%; 95%
CI, 87.1%-87.9%of thosewhowere aware]), and7634had their
bloodpressure controlled (13.2%; 95%CI, 12.9%-13.5% [32.5%;
95% CI, 31.9%-33.1% of those receiving medical treatment]).
Awareness, treatment, and control of hypertensionwere low-
est in LICs, particularly in Africa (Table 2).
Urban vs Rural
Awareness and treatment rates of hypertension were similar
in urban and rural communities of HICs and UMICs, but were
significantly lower in rural areasvsurbanareas inLICs (aware-
ness in urban LICs, 48.4% [95% CI, 41.0%-55.8%] vs aware-
ness in rural LICs, 31.2% [95% CI, 25.2%-38.0%]; and treat-
ment inurbanLICs, 36.1% [95%CI, 29.0%-43.9%]vs treatment
in rural LICs, 19.9% [95%CI, 15.2%-25.7%]). The proportion of
participants with controlled blood pressure was consistently
lower in rural areas vs urban areas in all countries (Table 3).
Age and Sex
Participants aged 50 years and older consistently had greater
awareness of their hypertension comparedwith younger par-
Table 3. Comparison of Hypertension Prevalence, Awareness, and Treatment by Population Density, Sex, and Agea
Countries
by Income
Level
% (95% CI)
Prevalence Awareness Treatment Control
Population
Density Urban Rural
P
Valueb Urban Rural
P
Valueb Urban Rural
P
Valueb Urban Rural
P
Valueb
HIC 36.4
(28.1-45.6)
40.2
(31.4-49.7)
<.001 48.3
(39.1-57.6)
47.2
(37.9-56.6)
.45 45.6
(35.8-55.8)
44.2
(34.4-54.5)
.35 17.6
(10.6-27.9)
16.1
(9.5-25.9)
.14
UMIC 45.2
(40.0-50.4)
46.9
(41.7-52.2)
.003 52.1
(46.9-57.4)
51.9
(46.6-57.2)
.86 46.1
(40.5-51.9)
46.9
(41.3-52.7)
.29 15.8
(11.9-20.7)
14.7
(11.0-19.4)
.08
LMIC 34.9
(30.3-39.7)
38.7
(33.9-43.7)
<.001 49.3
(44.2-54.4)
37.8
(33.1-42.7)
<.001 41.5
(36.3-47.0)
28.4
(24.0-33.1)
<.001 12.4
(9.3-16.4)
5.4
(4.0-7.4)
<.001
LIC 44.4
(37.1-51.9)
31.5
(25.4-38.4)
<.001 48.4
(41.0-55.8)
31.2
(25.2-38.0)
<.001 36.1
(29.0-43.9)
19.9
(15.2-25.7)
<.001 12.8
(8.4-19.0)
6.9
(4.4-10.7)
<.001
ALL 40.1
(36.7-43.6)
39.2
(35.8-42.6)
49.5
(46.0-53.0)
41.8
(38.4-45.3)
42.3
(38.6-46.1)
33.9
(30.5-37.4)
14.5
(12.0-17.5)
9.8
(8.0-12.0)
Sex Women Men Women Men Women Men Women Men
HIC 32.3
(24.5-41.2)
44.2
(35.0-53.9)
<.001 49.4
(40.3-58.6)
43.7
(34.9-52.9)
<.001 45.4
(35.8-55.4)
41.9
(32.6-51.8)
.007 18.5
(11.2-29.0)
13.6
(8.0-22.1)
<.001
UMIC 44.3
(39.1-49.6)
47.8
(42.5-53.1)
<.001 58.5
(53.4-63.5)
43.8
(38.7-49.1)
<.001 53.1
(47.5-58.6)
38.2
(33.1-43.7)
<.001 19.2
(14.7-24.8)
10.1
(7.5-13.6)
<.001
LMIC 36.1
(31.4-41.0)
37.3
(32.6-42.4)
.002 47.7
(42.8-52.8)
39.7
(35.0-44.6)
<.001 39.8
(34.8-45.1)
30.2
(25.8-35.0)
<.001 10.0
(7.5-13.3)
8.0
(5.9-10.8)
<.001
LIC 38.7
(31.8-46.1)
36.5
(29.7-43.8)
.003 44.7
(37.6-52.0)
36.4
(29.9-43.5)
<.001 30.9
(24.6-38.0)
26.7
(20.9-33.4)
<.001 10.8
(7.0-16.1)
9.4
(6.1-14.2)
.02
ALL 37.7
(34.4-41.2)
41.4
(37.9-44.9)
50.1
(46.7-53.6)
40.9
(37.6-44.3)
42.1
(38.5-45.8)
34.0
(30.7-37.4)
14.1
(11.6-17.0)
10.1
(8.3-12.3)
Agec Younger Older Younger Older Younger Older Younger Older
HIC 24.1
(17.9-31.7)
52.8
(43.4-62.0)
<.001 31.6
(24.0-40.4)
53.7
(44.5-62.7)
<.001 26.2
(19.0-35.0)
52.2
(42.3-62.0)
<.001 10.8
(6.2-18.1)
18.1 (11.0-28.4) <.001
UMIC 30.7
(26.5-35.4)
60.8
(55.8-65.6)
<.001 38.9
(34.0-44.1)
57.5
(52.4-62.6)
<.001 31.4
(26.7-36.6)
53.2
(47.6-58.7)
<.001 12.4
(9.2-16.5)
16.2
(12.2-21.1)
<.001
LMIC 24.1
(20.5-28.0)
50.8
(45.7-55.9)
<.001 31.4
(27.2-36.0)
49.4
(44.4-54.5)
<.001 23.2
(19.5-27.4)
41.3
(36.1-46.7)
<.001 6.3
(4.6-8.6)
9.9
(7.4-13.2)
<.001
LIC 26.3
(20.9-32.5)
48.8
(41.4-56.2)
<.001 30.6
(24.7-37.3)
44.2
(37.1-51.5)
<.001 19.4
(14.8-24.9)
32.6
(26.0-39.9)
<.001 8.9
(5.7-13.5)
10.0
(6.5-15.1)
.04
ALL 26.2
(23.6-29.0)
53.3
(49.8-56.8)
33.1
(30.0-36.3)
51.2
(47.8-54.7)
24.8
(22.1-27.8)
44.6
(41.0-48.3)
9.3
(7.6-11.4)
13.1
(10.8-15.9)
Abbreviations: BP, blood pressure; HIC, high-income country; LIC, low-income
country; LMIC, low–middle-income country; UMIC, upper–middle-income
country.
a Results are adjusted for covariates (age, sex, and population density) and
controlled for clustering. Unadjusted results reported by No. (%) are in eTable
7 (in Supplement).
b For prevalence, awareness, treatment, and control, there are significant
interactions (P < .001) of economic status of country × location (urban/rural),
× sex, and × age group.
c Younger and older age categories are specifically younger than aged 50 years
and aged 50 years and older.
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ticipants and had higher rates of treatment and control when
comparedwithyoungerparticipants.Womenconsistentlyhad
greater awareness of their hypertension and higher rates of
treatment and control than men (Table 3).
Education
Inmodelsmutually adjusted by age, sex, andurban/rural set-
ting, greater education was associated with greater aware-
ness and treatment in men but not women, and greater con-
trol in bothmenandwomen (Figure 1). Greater educationwas
associatedwith greater awareness and treatment in LICs only
and greater rates of control in HICs and LICs. Greater educa-
tion was associated with greater awareness, treatment, and
control in older, but not younger participants (eTables 9, 10,
11, and 12 in Supplement).
Blood Pressure–LoweringMedications
Overall, angiotensin-convertingenzyme(ACE) inhibitorsoran-
giotensin receptor blockers (ARBs) were the most commonly
used blood pressure–lowering agents (13.6%; 95% CI, 13.3%-
13.9%) with a similar proportion of participants with hyper-
tension (self-reported on treatment or BP ≥140/90 mm Hg)
using other bloodpressure–lowering agents (β-blockers, 8.2%
[95%CI, 8.0%-8.4%]; diuretics, 7.0%[95%CI, 6.8%-7.2%]; and
calciumantagonists, 8.2%[95%CI, 8.0%-8.4%]).However this
pattern varied across countries. Medications most com-
monlyused inHICs andUMICswereACE inhibitors andARBs,
diuretics andcalciumchannel blockers inLMICs, andβ-block-
ers in LICs (Figure 2).
Among the 23 510 participants who self-reported receiv-
ing treatment for hypertension, 7273 reported 2 ormore types
of blood pressure-lowering medications on their medication
lists (30.8% [95% CI, 30.2%-31.4%] or 12.5% of all with hyper-
tension [95% CI, 12.2%-12.8%]). The use of 2 ormoremedica-
tions was significantly lower in LICs compared with HICs,
UMICs, or LMICs (combinedP = <.001; inHICs, 18.1% [95%CI,
17.2%-19.1%]; inUMICs, 14.5%[95%CI, 14.0%-15.1%]; inLMICs,
14.1% [95% CI, 13.7%-14.6%]; and in LICs, only 1.6% [95% CI,
1.4%-1.8%]; eTable 5 in Supplement).
Theuseof 2 ormoremedications amonghypertensivepa-
tientswas slightlyhigher inwomencomparedwithmen (8.1%
[95% CI, 6.3%-10.4%] and 6.9% [95% CI, 5.3%-9.0%], respec-
Figure 1. Prevalence, Awareness, Treatment, and Control of Hypertension by Education
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Error bars indicate 95% CIs. For prevalence, awareness, control, and treatment,
there is a significant trend by education overall (P < .001). Younger and older
describe age categories (<50 years and50 years). A, P values were significant
in men and women (P < .001), older and younger participants (P < .001), urban
communities (P < .001), rural communities (P = .004), high-income
communities (HICs, P < .001), upper–middle-income communities (UMICs,
P < .001), lower–middle-income communities (LMICs, P = .048), and
low-income communities (LICs, P < .001). There were significant interactions of
sex × education (P < .001), age × education (P = .008), urban and rural
location × education (P < .001), and economic status of countries × education
(P < .001). B, P values were significant in men (P < .001), older participants
(P < .001), urban and rural communities (P < .001), LICs (P < .001), but not in
other groups. There were significant interactions of sex × education (P < .001),
urban and rural location × education (P = .001), and economic status of
countries × education (P < .001). C, P values were significant in men (P < .001),
older participants (P < .001), urban and rural communities (P < .001), in LICs
(P < .001), but not in other groups. There were significant interactions of
sex × education (P < .001), age × education (P < .001), urban and rural
location × education (P = .001), and economic status of countries × education
(P < .001). D, P values were significant in women andmen (P < .001), older
participants (P < .001), urban and rural communities (P < .001), HICs (P = .01),
LICs (P < .001), but not in other groups. There were significant interactions of
age × education (P < .001), urban and rural location × education (P = .005), and
economic status of countries × education (P < .001).
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tively;P <.001 for comparison), older comparedwith younger
participants (9.5% [95% CI, 7.4%-12.2%] and 4.5% [95% CI,
3.5%-5.9%], respectively; P <.001 for comparison) and urban
vs rural areas (8.0% [95% CI, 6.2%-10.3%] and 7.4% [95% CI,
5.7%-9.5%], respectively;P = .005 for comparison). Theuseof
2 ormoremedications alsowas greaterwith increased educa-
tion (eTable 6 in Supplement).
Discussion
This study founda large gapbetweenbothdetection and con-
trol of hypertension across all countries studied. It shows that
while initial therapy was started in the largemajority of indi-
vidualswhoaredetected tohavehypertension, control inpar-
ticipants receiving treatment was very poor. The use of com-
binationtherapies,generally requiredtoachievebloodpressure
control,18 was low. Awareness, treatment, and control were
lower in LICs comparedwith other countries and in rural set-
tings of LMICs and LICs compared with urban ones. Despite
men having higher rates of hypertension, women consis-
tently had higher awareness, treatment, and control of their
hypertension, consistent with a large body of research on sex
and health-seeking behavior.19 Also participants with more
educationhadgreater awareness, treatment, andcontrol, par-
ticularly in LICs.
The rates of hypertension prevalence, awareness, treat-
ment, and control found in this study are generally consis-
tentwith findings in those countrieswithexistingdata.6,20 For
example, rates of treatment among individuals aware of their
hypertension ina2008/2009survey inCanadawas82%,which
was similar to that from theCanadian cohort in PURE.21 In the
China National Nutrition and Health Survey of 2002, aware-
ness of hypertension was lower (28%) but the proportion of
those awareon treatment (78%)was similar.22 In a study in In-
dia from2004-2007, a survey of 4608 rural andurbanwomen
found 42.8% aware of hypertension, which was similar to
PURE, but reported lower rates of treatment (38.6% of those
aware).23 The apparently higher prevalence of hypertension
measured in this study (40.7%) comparedwithestimates from
the Global Burden of Disease study24 in 2000 of 26.4% (95%
CI, 26.0%-26.8%) for 20- to 80-year olds is due to the older age
of the participants in PURE (>35 years). When we age-
standardizedto theWHOworldpopulation,15 theoverallpreva-
lence of hypertension in the PURE study was 27.7%, which is
similar to theGlobal Burden of Disease estimates24 and to the
results of a recent systematic analysis of health surveys from
199 countries for individuals aged 25 years and older in 2008
(SBP ≥140 mm Hg or DBP ≥ 90 mm Hg) of 29% (95% CI, 27%-
31%) inmenand 25% (95%CI, 23%-27%) inwomen.6 This sug-
gests that there is unlikely tohavebeenmajor biases in the se-
lection of communities and individuals in the countries
included in this study and therefore, our data can be consid-
ered to be reasonably reflective of the prevalence in the ur-
ban and rural areas of these diverse countries.
The widespread lack of hypertension awareness (a mea-
sure of hypertension case identification) and poor control (a
measureof inadequate treatment) in all countries studied, de-
spite the identificationandcontrol of bloodpressurebeingpri-
oritized by many national and global organizations and de-
spite theavailabilityof inexpensiveandeffectivemedications,
is concerning.25,26 The low rates of detectionmay be because
few individuals have their blood pressure checked either
through routinehealth assessmentor screeningprogramsand
may be due to difficulties or costs in accessing health care.
The lowest rates of use of blood pressure–loweringmedi-
cationswereobserved inLICs.Although low-costgenericblood
pressure–lowering medications are available in LICs, pos-
sible barriers to use of medications are still affordability (as a
proportion of local income), lack of drug inventory, distance
to clinics, and the costs to see physicians. Hence, models of
care that shift thedetection and initial treatment of hyperten-
sion tononphysicianhealthworkers shouldbeconsidered.27-29
Effectiveness of these models of care have been demon-
strated inmanagement of other conditions such asHIV in de-
velopingcountries.30-32However, evenamong individualswho
have received treatment, there is poor blood pressure con-
trol. This suggests ineffectiveness inour current treatment ap-
proach, which is largely based on the use of single drugs. In-
stead, strategies such as using combination therapy for the
initial treatment of hypertension may be required.28
In LICs, awareness, treatment, and control were lower in
participantswithprimaryornoeducation,most likely reflect-
ing a combinationof lowsocioeconomic status,whichmay in-
fluenceaccess to care, lackofknowledgeof the sequelaeofun-
controlled hypertension, and differing values with respect to
the importanceof the future.33,34 Educationwasusedas a sur-
rogate for socioeconomic status in this analysis and although
this is limited, similar social patterningofhypertensionpreva-
lence has been recently reported in some LICs.35
Strengths and Limitations
To our knowledge, this is currently the largest multicountry
study inwhich blood pressurewasmeasured using standard-
izedmethods across all study centers. It involves a largenum-
Figure 2. Types of Treatments Used for Hypertension in Countries
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ber of low- and middle-income countries, involves both ur-
ban and rural communities, and participants were identified
fromcommunities andnot fromclinics or hospitals. It also re-
corded data on the number and types of drugs used, which is
generally not collected to this detail in other surveys of hy-
pertension.
This study’s major limitation is that the sampling frame-
work in each country was not nationally representative, and
therefore caution is needed in extrapolating the information
as being representative of the status in each country. Never-
theless, ouroverall prevalenceofhypertension is similar to the
globalprevalenceestimates24afteradjusting forage,andthere-
fore suggests no major biases due to the nonrandom selec-
tion of communities or countries included in PURE. Al-
though a random selection of countries from each part of the
world that included different economic levels and identifica-
tion of a random set of communities within them would be
ideal fromamethodological perspective, such an approach is
not practical given the existing poor research infrastructure
inmanypartsof theworld.Theresponse ratewas lower inLICs,
but the characteristics of enrolled to eligible participantswere
similar in HICs, UMICs, LMICs, and LICs. Diagnosis of hyper-
tension was based on measures and history taken at a single
visit; however, multiple visits are impractical for large-scale
studies andour approach is similar to that ofmany epidemio-
logical studies.
Conclusions
In this cross-sectional analysis of amultinational studypopu-
lation, 46.5%of participantswithhypertensionwere aware of
the diagnosis, while blood pressure was controlled among
32.5%of those being treated. These findings suggest that sub-
stantial improvement in hypertension diagnosis and treat-
ment is needed.
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